A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

  • Cancer
  • Colorectal Cancer (CRC)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • Belgium
Trial Identifier:

NCT02673710 ML29985

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02673710,ML29985 Trial Identifier
      No intervention Treatments
      Metastatic Colorectal Cancer Condition
      Official Title

      A Multicenter Non-Interventional Study Exploring the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With a Chemotherapy Combined With Bevacizumab

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Patients treated in first line with bevacizumab for whom it is decided, and who are clinically considered eligible, to continue the treatment with bevacizumab beyond PD1.
      • Women of childbearing potential have to use effective contraception during (and up to 6 months after) treatment.
      • Availability of specific retrospective data at diagnosis and during 1st line treatment
      Exclusion Criteria
      • Patients who are participating or participated in first line in any other interventional clinical trial involving non-standard of care procedures impacting the body composition
      • Dementia or another mental condition making it impossible to fill out questionnaires

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Colorectal Cancer (CRC)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now